Cancer, a complex group of diseases characterized by uncontrolled cell proliferation, remains a significant global health challenge. While traditional cancer treatments offer broad-spectrum efficacy, they often induce substantial side effects due to their non-specific targeting.  Recent advancements in understanding the genetic underpinnings of cancer have paved the way for a paradigm shift towards personalized medicine, promising more effective and less toxic therapies. This research paper explores the significant progress made in elucidating the genetic basis of cancer and its translation into personalized approaches.  We will examine the crucial role of next-generation sequencing (NGS) in identifying specific oncogenic mutations and characterizing tumor heterogeneity, emphasizing its impact on diagnostic accuracy and treatment selection.  Furthermore, we will analyze the emergence of novel therapeutic strategies, including targeted therapies, immunotherapy, and gene editing technologies, highlighting their potential to revolutionize cancer treatment based on an individual's unique genetic profile. Finally, we will discuss the ongoing challenges and future directions in this rapidly evolving field, particularly concerning the ethical implications of personalized cancer medicine and the need for robust clinical trials to validate its efficacy and accessibility.